NEW YORK (GenomeWeb) – GeneNews announced today that it has signed a deal to offer three of its cancer diagnostic tests through healthcare services management firm NueHealth.
Under the terms of the three-year arrangement, GeneNews' blood-based ColonSentry, earlyCDT-Lung and Prostate Health Index tests — which are designed for early patient risk stratification in colorectal, lung, and prostate cancers, respectively — will be offered to patients at NueHealth's provider-owned care centers.
GeneNews will process patient samples at its clinical reference lab and be responsible supplying testing kits, generating patient reports, and providing ongoing consultation. The tests will be provided for a flat fee, with NueHealth handling client billing.
Additional terms of the partnership were not disclosed, but GeneNews said that it is expected to "significantly accelerate" its path to positive cash flow and net profitability.